pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ZEPBOUND · news · pharmadog
← back to ZEPBOUND
News mentioning ZEPBOUND
109
stories
2d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
2d
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
2d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
3d
3 takeaways from a European obesity scientific meeting
biopharma dive
3d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
3d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
4d
Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial
raps
4d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
4d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
4d
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
4d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
4d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
5d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
5d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
5d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
6d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
6d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
10d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
10d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
12d
Viking shares surge on updated obesity drug data
biopharma dive
13d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
13d
Novo talks up drug launches in effort to win back investors
biopharma dive
13d
Novo offers low-dose CagriSema data as approval decision looms
endpoints
13d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
18d
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
20d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
21d
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
21d
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
25d
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
biospace
25d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
← prev
page 1 of 4
next →
